Advertisement – This document is an advertisement for purposes of the Prospectus Regulations (as defined below).
This announcement is not intended for distribution, directly or indirectly, within or within the United States or any other jurisdiction where such distribution is prohibited by applicable law.
Brussels (Belgium), November 7, 2023 – 8:30 am (CET) – Regulatory Information
Today, UCB SA/NV (“UCB“And that”Issuer”) announces the opening of a public offering of bonds with a maturity of 6 years for a minimum amount of EUR 100 million and a maximum amount of EUR 300 million (“Note”). The bond will be issued to the public in Belgium and the Grand Duchy of Luxembourg under UCB’s recently updated Euro Medium Term Bond Program, with a subscription period from 09:00 (CET) to 1:00 p.m. on November 9, 2023. Ends November 2023, 5:30pm CET (subject to early termination). Belfius Bank (Dutch/France), BNP Paribas Fortis (Dutch/France), ING Bank NV, Belgium Branch (Dutch/France) and KBC Bank (Dutch/France) are acting as joint lead managers for this transaction (‘manager”). The bonds will be listed on Euronext Brussels and will be submitted for trading on the Euronext Brussels regulated market from the date of issue.
The main features of Notes are explained below.
- Different fees may apply to Accredited Investors as detailed in the Final Terms.
risk warning
The Notes constitute an unsecured and unguaranteed debt instrument. By subscribing to a bond, an investor lends money to the issuer, and the issuer promises to pay interest and repay the principal of the bond on November 21, 2029. If the issuer becomes bankrupt or defaults, investors may not be able to recover amounts to which they are entitled. There is a risk of losing all or part of your investment.
Investing in Notes involves certain risks and may not be suitable for all investors. Prospective investors should carefully consider whether an investment in the Notes is suitable for them in the light of their own knowledge and financial experience and, if appropriate, obtain professional advice. Prospective investors should read the Base Prospectus and the Final Terms (each defined below), as supplemented by Supplement No. 1, in their entirety, and in particular carefully consider the risk factors set forth in the “Risk Factors” section of the Base Prospectus. Must read. , as supplemented in Supplement No. 1, you should fully understand the potential risks and rewards associated with a decision to invest in the Notes before making any investment decision.
subscription
The minimum subscription amount and face value is 1,000 euros. The subscription period runs from 9:00 AM (CET) on November 9, 2023 to 5:30 PM (CET) on November 13, 2023, subject to early termination, as early as November 2023. May end on Monday 9th at 5:30pm CET. minimum sales period). All subscriptions validly introduced by the retail investor to the manager before the end of the minimum sales period will be taken into account at the time of bond allocation, taking into account that a pro rata reduction may apply in case of excess subscriptions To do. Therefore, retail investors are advised to subscribe to the Notes by 5:30 pm (CET) on the first day of the subscription period.
To subscribe to the bond or obtain further information, investors should contact Belfius Bank (Dutch/France), BNP Paribas Fortis (Dutch/France), ING Bank NV, Belgium Branch (Dutch/France) and KBC Bank (Dutch/France).
cost
All retail investors are subject to a 1.875% fee (included in the issue price of the bond). Financial services related to the Notes are provided free of charge by the Manager. Investors should educate themselves about the costs that financial institutions may charge.
Base Prospectus, Supplement No. 1 and Final Terms
The base prospectus has been approved by the Belgian Financial Services and Markets Authority (“FSMA”) Regulation (EU) 2017/1129 (as amended, “prospectus rules”) October 17, 2023 (“Basic prospectus”). Supplement No. 1 to the Base Prospectus was approved by FSMA on October 24, 2023 (“Supplementary number 1FSMA has approved only the Base Prospectus and Supplement N°1 as meeting the standards of completeness, understandability and consistency imposed by the Prospectus Regulation. Approval by FSMA is based on the UCB or Notes. They should not be considered as an endorsement of quality. Investors should make their own assessment of the suitability of investing in the Notes. Before making any investment decision, potential investors should read Supplementary No. 1 You should carefully read and understand the entire Base Prospectus and Final Terms as supplemented by, and in particular the “Risk Factors” section of the Base Prospectus. the potential risks and rewards associated with the decision to invest in the Notes;
Approval of the Base Prospectus and Supplement No. 1 is from FSMA. Fiscal and Financial Oversight Committee In its capacity as the competent authority for the purposes of the Prospectus Regulation in connection with the provision of official documents to the public in the Grand Duchy of Luxembourg.
Final Terms relating to the Base Prospectus, Supplement No. 1 and Notes (“Final conditions”) contains issue-specific summaries in English, Dutch, and French, available at the following website: UCB Belfius Bank website (Dutch/France), BNP Paribas Fortis (Dutch/France), ING Bank NV, Belgium Branch (Dutch/France) and KBC Bank (Dutch/France).
complaint
If you have a complaint, please contact us at:
Please contact your local Belfius branch, your financial advisor or email [email protected].
If you are not satisfied with our response, please contact Belfius Bank NV-SA, Negotiation (number 7913), Karel Rogierplein 11, 1210 Brussels or by email at [email protected].
BNP Paribas Fortis Complaints Department, Warandeberg 3, 1000 Brussels or email [email protected].
ING, Customer Service, Sint-Michielswarande 60, 1040 Brussels or email [email protected].
Please contact your nearest KBC Bank branch.
If you feel that your suggestion or complaint cannot be addressed, please
If you are dissatisfied with your KBC Bank branch or with the proposed solution, please contact KBC Complaint Management (Brusselsesteenweg 100, 3000 Leuven) (phone number 0800 62 084) or email [email protected].
If you cannot find a quick solution after contacting the services listed above, please contact the Financial Disputes Ombudsman, North Gate II, Koning Albert II-laan 8, box 2, 1000 Brussels, telephone number 02 545 77 70. Or email us at [email protected].
Disclaimer
This announcement is not intended for distribution, directly or indirectly, within or within the United States or any other jurisdiction where such distribution is prohibited by applicable law.
This announcement does not constitute an offer to sell or subscribe for any securities, or a solicitation of an offer to buy or subscribe for any securities in any jurisdiction in which such offer, solicitation, or subscription for securities may be made. , no sale or underwriting of securities shall be made. Any sale or offer shall be unlawful without prior application or qualification under the financial laws of such jurisdiction. The issuance, subscription or purchase of securities is subject to special legal or regulatory restrictions in certain jurisdictions. UCB is not responsible if anyone violates any such restrictions.
No public offering of the securities referred to in this document will be made in the United States. The securities referenced in this document have not been and will not be registered under the United States Securities Act of 1933, as amended.securities law”) or in the United States, to or for the account or benefit of a United States person, except pursuant to an exemption from registration requirements and pursuant to the securities laws of any state or jurisdiction of the United States; It cannot be offered or sold. Securities law provisions. Terms used in this paragraph have the meanings given to them by Regulation S under the Securities Act. The securities referred to in this document have not been approved or disapproved by the SEC, any other state securities commission, or any other U.S. regulatory agency, and no such authority has determined that this proposed offering is appropriate. We have not evaluated the suitability or accuracy of this proposal. document. Any statement to the contrary is a criminal offense in the United States.
This document is not an offering document or prospectus relating to the offering of securities by UCB. Investors should not accept offers for or acquire securities referred to herein except in reliance on the information contained in the Base Prospectus, as supplemented by Supplement No. 1 and the Final Terms. not. This document is an advertisement for purposes of the Prospectus Regulations.
If you have any questions regarding this press release or would like more information, please contact UCB.
PR for investors
Antje Witte
Phone +32 2 559 94 14
[email protected]
Julien Bayet
Phone +32 2 559 95 80
[email protected]
corporate communication
Laurent Schott
T+32 2 559 92 64
[email protected]
About UCB
UCB, Brussels, Belgium (www.ucb.com) is focused on discovering and developing innovative medicines and solutions to transform the lives of people living with serious diseases of the immune or central nervous system. A global biopharmaceutical company. The company, which has around 8,700 employees in around 40 countries, generated revenues of 5.5 billion euros in 2022. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.
